31 results on '"Bouwmans, Pim"'
Search Results
2. Post COVID-19 condition imposes significant burden in patients with advanced chronic kidney disease: A nested case-control study
- Author
-
Bouwmans, Pim, Malahe, S.Reshwan K., Messchendorp, A. Lianne, Vart, Priya, Imhof, Céline, Sanders, Jan-Stephan F., Gansevoort, Ron T., de Vries, Aiko P.J., Abrahams, Alferso C., Bemelman, Frederike J., Vervoort, Johanna P.M., Hilbrands, Luuk B., ten Dam, Marc A.G.J., van den Dorpel, René M.A., Rispens, Theo, Steenhuis, Maurice, Reinders, Marlies E.J., and Hemmelder, Marc H.
- Published
- 2024
- Full Text
- View/download PDF
3. The role of interleukin-21 in COVID-19 vaccine–induced B cell–mediated immune responses in patients with kidney disease and kidney transplant recipients
- Author
-
Abrahams, Alferso C., Baas, Marije C., Mattheussens, Wouter B., Philipsen, Ria H.L.A., Bouwmans, Pim, Hemmelder, Marc H., ten Dam, Marc A.G.J., Gommers, Lennert, Mourik, Djenolan van, Bogers, Susanne, van Dijk, Laura L.A., Standaar, Dorien, der Heiden, Marieke van, Adema, Yvonne M.R., Boer-Verschragen, Marieken J., Rots, Nynke, de Vries, Aiko P.J., Malahe, S. Reshwan K., Hartog, Yvette den, Rietdijk, Wim J.R., van Baarle, Debbie, de Kuiper, Ronella, Reijerkerk, Derek, Ras, Alicia M., Geers, Daryl, Diavatopoulos, Dimitri A., Messchendorp, A. Lianne, van der Molen, Renate G., Remmerswaal, Ester B.M., Bemelman, Frederike J., Gansevoort, Ron T., Hilbrands, Luuk B., Sanders, Jan-Stephan, GeurtsvanKessel, Corine H., Kho, Marcia M.L., de Vries, Rory D., Reinders, Marlies E.J., and Baan, Carla C.
- Published
- 2023
- Full Text
- View/download PDF
4. Adherence to preventive measures after SARS-CoV-2 vaccination and after awareness of antibody response in kidney transplant recipients in the Netherlands: a nationwide questionnaire study
- Author
-
Imhof, C., Idzinga, C., Siegert, C., Baan, C.C., Konings, C.J.A.M., van Kessel, C., van Baarle, D., Diavatopoulos, D.A., Standaar, D., ten Hoope, E., Til, E., Remmerswaal, E.B.M., van der Klis, F., Fritsen, H.R., Stijnman, I., Brinkman, J.N., Cheng, J., den Biggelaar, L., ten Dam, M., Steenhuis, M., Zwerink, M., Braks, M.H.J., Willems, M., Kho, M.L., Rots, N., Vart, P., van der Molen, R.G., van den Dorpel, R.M.A., Malaha, R.S.R.K., ter Meulen, R.C.G., Rispens, T., Steenvoorden, T., de Ronde, T., Peters, V.J.P., Konijn, W.S., Janssen, W.M.T., Bos, W.J., Adema, Y.M.R., Vegting, Y., Frölke, Sophie C., Bouwmans, Pim, Messchendorp, A. Lianne, Vervoort, Johanna P.M., Abrahams, Alferso C., de Vries, Aiko P.J., Nieuwkerk, Pythia T., Hemmelder, Marc H., Gansevoort, Ron T., Hilbrands, Luuk B., Reinders, Marlies E.J., Sanders, Jan-Stephan F., Bemelman, Frederike J., and Geerlings, Suzanne E.
- Published
- 2023
- Full Text
- View/download PDF
5. Alternative strategies to increase the immunogenicity of COVID-19 vaccines in kidney transplant recipients not responding to two or three doses of an mRNA vaccine (RECOVAC): a randomised clinical trial
- Author
-
Abrahams, Alferso C., Baas, Marije C., Bouwmans, Pim, ten Dam, Marc A.G.J., Gommers, Lennert, Standaar, Dorien, van der Heiden, Marieke, Adema, Yvonne M.R., Boer-Verschragen, Marieken J., Mattheussens, Wouter B., Philipsen, Ria H.L.A., van Mourik, Djenolan, Bogers, Susanne, van Dijk, Laura L.A., Rots, Nynke, Smits, Gaby, Kuijer, Marjan, Hemmelder, Marc H., Kho, Marcia M L, Messchendorp, A Lianne, Frölke, Sophie C, Imhof, Celine, Koomen, Vera JCH, Malahe, S Reshwan K, Vart, Priya, Geers, Daryl, de Vries, Rory D, GeurtsvanKessel, Corine H, Baan, Carla C, van der Molen, Renate G, Diavatopoulos, Dimitri A, Remmerswaal, Ester B M, van Baarle, Debbie, van Binnendijk, Rob, den Hartog, Gerco, de Vries, Aiko P J, Gansevoort, Ron T, Bemelman, Frederike J, Reinders, Marlies E J, Sanders, Jan-Stephan F, and Hilbrands, Luuk B
- Published
- 2023
- Full Text
- View/download PDF
6. #2681 Impact of sharing anti-SARS-CoV-2 antibody levels with Kidney Transplant Recipients on adherence to preventive measures and incidence of COVID-19
- Author
-
Bouwmans, Pim, primary, Sanders, Jan-Stephan F, additional, Hilbrands, Luuk, additional, Reinders, Marlies, additional, Bemelman, Frederike, additional, Abrahams, Alferso, additional, De Vries, Aiko, additional, Brandts, Lloyd, additional, Vervoort, Hanneke, additional, Gansevoort, Ronald, additional, Hemmelder, Marc, additional, and Messchendorp, Lianne, additional
- Published
- 2024
- Full Text
- View/download PDF
7. Incidence and Severity of COVID-19 in Relation to Anti-Receptor-Binding Domain IgG Antibody Level after COVID-19 Vaccination in Kidney Transplant Recipients
- Author
-
Messchendorp, A. Lianne, Sanders, Jan Stephan F., Abrahams, Alferso C., Bemelman, Frederike J., Bouwmans, Pim, van den Dorpel, René M.A., Hilbrands, Luuk B., Imhof, Céline, Reinders, Marlies E.J., Rispens, Theo, Steenhuis, Maurice, ten Dam, Marc A.G.J., Vart, Priya, de Vries, Aiko P.J., Hemmelder, Marc H., Gansevoort, Ron T., Messchendorp, A. Lianne, Sanders, Jan Stephan F., Abrahams, Alferso C., Bemelman, Frederike J., Bouwmans, Pim, van den Dorpel, René M.A., Hilbrands, Luuk B., Imhof, Céline, Reinders, Marlies E.J., Rispens, Theo, Steenhuis, Maurice, ten Dam, Marc A.G.J., Vart, Priya, de Vries, Aiko P.J., Hemmelder, Marc H., and Gansevoort, Ron T.
- Abstract
Kidney transplant recipients (KTRs) elicit an impaired immune response after COVID-19 vaccination; however, the exact clinical impact remains unclear. We therefore analyse the relationship between antibody levels after vaccination and the risk of COVID-19 in a large cohort of KTRs. All KTRs living in the Netherlands were invited to send a blood sample 28 days after their second COVID-19 vaccination for measurement of their IgG antibodies against the receptor-binding domain of the SARS-CoV-2 spike protein (anti-RBD IgG). Information on COVID-19 was collected from the moment the blood sample was obtained until 6 months thereafter. Multivariable Cox and logistic regression analyses were performed to analyse which factors affected the occurrence and severity (i.e., hospitalization and/or death) of COVID-19. In total, 12,159 KTRs were approached, of whom 2885 were included in the analyses. Among those, 1578 (54.7%) became seropositive (i.e., anti-RBD IgG level >50 BAU/mL). Seropositivity was associated with a lower risk for COVID-19, also after adjusting for multiple confounders, including socio-economic status and adherence to COVID-19 restrictions (HR 0.37 (0.19–0.47), p = 0.005). When studied on a continuous scale, we observed a log-linear relationship between antibody level and the risk for COVID-19 (HR 0.52 (0.31–0.89), p = 0.02). Similar results were found for COVID-19 severity. In conclusion, antibody level after COVID-19 vaccination is associated in a log-linear manner with the occurrence and severity of COVID-19 in KTRs. This implies that if future vaccinations are indicated, the aim should be to reach for as high an antibody level as possible and not only seropositivity to protect this vulnerable patient group from disease.
- Published
- 2024
8. Post COVID-19 condition imposes significant burden in patients with advanced chronic kidney disease:A nested case-control study
- Author
-
Bouwmans, Pim, Malahe, S Reshwan K, Messchendorp, A Lianne, Vart, Priya, Imhof, Céline, Sanders, Jan-Stephan F, Gansevoort, Ron T, de Vries, Aiko P J, Abrahams, Alferso C, Bemelman, Frederike J, Vervoort, Johanna P M, Hilbrands, Luuk B, Ten Dam, Marc A G J, van den Dorpel, René M A, Rispens, Theo, Steenhuis, Maurice, Reinders, Marlies E J, Hemmelder, Marc H, Bouwmans, Pim, Malahe, S Reshwan K, Messchendorp, A Lianne, Vart, Priya, Imhof, Céline, Sanders, Jan-Stephan F, Gansevoort, Ron T, de Vries, Aiko P J, Abrahams, Alferso C, Bemelman, Frederike J, Vervoort, Johanna P M, Hilbrands, Luuk B, Ten Dam, Marc A G J, van den Dorpel, René M A, Rispens, Theo, Steenhuis, Maurice, Reinders, Marlies E J, and Hemmelder, Marc H
- Abstract
Background: The burden of post COVID-19 condition (PCC) is not well studied in patients with advanced kidney disease. Methods: A large prospective cohort of SARS-CoV-2 vaccinated patients with chronic kidney disease stages G4–G5 (CKD G4/5), on dialysis, and kidney transplant recipients (KTR) were included. Antibody levels were determined after vaccination. Presence of long-lasting symptoms was assessed in patients with and without prior COVID-19 and compared using logistic regression. In patients with prior COVID-19, PCC was defined according to the WHO definition. Results: Two hundred sixteen CKD G4/5 patients, 375 dialysis patients, and 2005 KTR were included. Long-lasting symptoms were reported in 204/853 (24%) patients with prior COVID-19 and in 297/1743 (17%) patients without prior COVID-19 (aOR: 1.45 (1.17–1.78)], P < 0.001). PCC was prevalent in 29% of CKD G4/5 patients, 21% of dialysis patients, and 24% of KTR. In addition, 69% of patients with PCC reported (very) high symptom burden. Odds of PCC was lower per 10-fold increase in antibody level after vaccination (aOR 0.82 [0.70–0.96], P = 0.01) and higher in case of COVID-19 related hospital admission (aOR 4.64 [2.61–8.25], P = 0.003). Conclusions: CKD G4/5 patients, dialysis patients, and KTR are at risk for PCC with high symptom burden after SARS-CoV-2 vaccination, especially if antibody levels are low and in case of hospitalization due to COVID-19.
- Published
- 2024
9. Predictors of Nonseroconversion to SARS-CoV-2 Vaccination in Kidney Transplant Recipients
- Author
-
Frölke, Sophie C., Bouwmans, Pim, Messchendorp, A. Lianne, Geerlings, Suzanne E., Hemmelder, Marc H., Gansevoort, Ron T., Hilbrands, Luuk B., Reinders, Marlies E.J., Sanders, Jan-Stephan F., Bemelman, Frederike J., and Peters-Sengers, Hessel
- Published
- 2022
- Full Text
- View/download PDF
10. SARS-CoV-2-specific immune responses converge in kidney disease patients and controls with hybrid immunity.
- Author
-
Aguilar-Bretones, Muriel, den Hartog, Yvette, van Dijk, Laura L. A., Malahe, S. Reshwan K., Dieterich, Marjolein, Mora, Héctor Tejeda, Mueller, Yvonne M., Koopmans, Marion P. G., Reinders, Marlies E. J., Baan, Carla C., van Nierop, Gijsbert P., de Vries, Rory D., RECOVAC Consortium, Abrahams, Alferso C., Baas, Marije C., Hemmelder, Marc H., Bouwmans, Pim, ten Dam, Marc A. G. J., Gommers, Lennert, and de Vries, Aiko P. J.
- Subjects
IMMUNE response ,KIDNEY diseases ,MATERNALLY acquired immunity ,IMMUNITY ,T cells ,DEAD ,CHRONIC kidney failure ,HEMODIALYSIS ,ERYTHROPOIETIN receptors - Abstract
Healthy individuals with hybrid immunity, due to a SARS-CoV-2 infection prior to first vaccination, have stronger immune responses compared to those who were exclusively vaccinated. However, little is known about the characteristics of antibody, B- and T-cell responses in kidney disease patients with hybrid immunity. Here, we explored differences between kidney disease patients and controls with hybrid immunity after asymptomatic or mild coronavirus disease-2019 (COVID-19). We studied the kinetics, magnitude, breadth and phenotype of SARS-CoV-2-specific immune responses against primary mRNA-1273 vaccination in patients with chronic kidney disease or on dialysis, kidney transplant recipients, and controls with hybrid immunity. Although vaccination alone is less immunogenic in kidney disease patients, mRNA-1273 induced a robust immune response in patients with prior SARS-CoV-2 infection. In contrast, kidney disease patients with hybrid immunity develop SARS-CoV-2 antibody, B- and T-cell responses that are equally strong or stronger than controls. Phenotypic analysis showed that Spike (S)-specific B-cells varied between groups in lymph node-homing and memory phenotypes, yet S-specific T-cell responses were phenotypically consistent across groups. The heterogeneity amongst immune responses in hybrid immune kidney patients warrants further studies in larger cohorts to unravel markers of long-term protection that can be used for the design of targeted vaccine regimens. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. The role of interleukin-21 in COVID-19 vaccine–induced B cell–mediated immune responses in patients with kidney disease and kidney transplant recipients
- Author
-
Malahe, S. Reshwan K., primary, Hartog, Yvette den, additional, Rietdijk, Wim J.R., additional, van Baarle, Debbie, additional, de Kuiper, Ronella, additional, Reijerkerk, Derek, additional, Ras, Alicia M., additional, Geers, Daryl, additional, Diavatopoulos, Dimitri A., additional, Messchendorp, A. Lianne, additional, van der Molen, Renate G., additional, Remmerswaal, Ester B.M., additional, Bemelman, Frederike J., additional, Gansevoort, Ron T., additional, Hilbrands, Luuk B., additional, Sanders, Jan-Stephan, additional, GeurtsvanKessel, Corine H., additional, Kho, Marcia M.L., additional, de Vries, Rory D., additional, Reinders, Marlies E.J., additional, Baan, Carla C., additional, Abrahams, Alferso C., additional, Baas, Marije C., additional, Mattheussens, Wouter B., additional, Philipsen, Ria H.L.A., additional, Bouwmans, Pim, additional, Hemmelder, Marc H., additional, ten Dam, Marc A.G.J., additional, Gommers, Lennert, additional, Mourik, Djenolan van, additional, Bogers, Susanne, additional, van Dijk, Laura L.A., additional, Standaar, Dorien, additional, der Heiden, Marieke van, additional, Adema, Yvonne M.R., additional, Boer-Verschragen, Marieken J., additional, Rots, Nynke, additional, and de Vries, Aiko P.J., additional
- Published
- 2023
- Full Text
- View/download PDF
12. Adherence to preventive measures after SARS-CoV-2 vaccination and after awareness of antibody response in kidney transplant recipients in the Netherlands: a nationwide questionnaire study
- Author
-
Frölke, Sophie C., primary, Bouwmans, Pim, additional, Messchendorp, A. Lianne, additional, Vervoort, Johanna P.M., additional, Abrahams, Alferso C., additional, de Vries, Aiko P.J., additional, Nieuwkerk, Pythia T., additional, Hemmelder, Marc H., additional, Gansevoort, Ron T., additional, Hilbrands, Luuk B., additional, Reinders, Marlies E.J., additional, Sanders, Jan-Stephan F., additional, Bemelman, Frederike J., additional, Geerlings, Suzanne E., additional, Imhof, C., additional, Idzinga, C., additional, Siegert, C., additional, Baan, C.C., additional, Konings, C.J.A.M., additional, van Kessel, C., additional, van Baarle, D., additional, Diavatopoulos, D.A., additional, Standaar, D., additional, ten Hoope, E., additional, Til, E., additional, Remmerswaal, E.B.M., additional, van der Klis, F., additional, Fritsen, H.R., additional, Stijnman, I., additional, Brinkman, J.N., additional, Cheng, J., additional, den Biggelaar, L., additional, ten Dam, M., additional, Steenhuis, M., additional, Zwerink, M., additional, Braks, M.H.J., additional, Willems, M., additional, Kho, M.L., additional, Rots, N., additional, Vart, P., additional, van der Molen, R.G., additional, van den Dorpel, R.M.A., additional, Malaha, R.S.R.K., additional, ter Meulen, R.C.G., additional, Rispens, T., additional, Steenvoorden, T., additional, de Ronde, T., additional, Peters, V.J.P., additional, Konijn, W.S., additional, Janssen, W.M.T., additional, Bos, W.J., additional, Adema, Y.M.R., additional, and Vegting, Y., additional
- Published
- 2023
- Full Text
- View/download PDF
13. #3852 INCIDENCE AND SEVERITY OF COVID-19 IN RELATION TO ANTI-RBD IGG ANTIBODY LEVEL AFTER COVID-19 VACCINATION IN KIDNEY TRANSPLANT RECIPIENTS
- Author
-
Messchendorp, Lianne, primary, Sanders, Jan-Stephan, additional, Abrahams, Alferso C, additional, Bemelman, Frederike, additional, Bouwmans, Pim, additional, Dorpel van den, René, additional, Hilbrands, Luuk, additional, Imhof, Celine, additional, Reinders, Marlies, additional, Rispens, Theo, additional, Steenhuis, Maurice, additional, Dam, Marc Ten, additional, Vart, Priya, additional, De Vries, Aiko, additional, Hemmelder, Marc, additional, and Gansevoort, Ronald, additional
- Published
- 2023
- Full Text
- View/download PDF
14. #3738 KIDNEY TRANSPLANT RECIPIENTS BECOME LESS ADHERENT TO PREVENTIVE MEASURES AFTER SARS‑COV‑2 VACCINATION AND AFTER AWARENESS OF ANTIBODY RESPONSE
- Author
-
Frölke, Sophie, primary, Bouwmans, Pim, additional, Messchendorp, Lianne, additional, Vervoort, Hanneke, additional, Nieuwkerk, Pythia, additional, Abrahams, Alferso C, additional, De Vries, Aiko, additional, Hemmelder, Marc, additional, Gansevoort, Ronald, additional, Hilbrands, Luuk, additional, Reinders, Marlies, additional, Sanders, Jan-Stephan, additional, Bemelman, Frederike, additional, and Geerlings, Suzanne, additional
- Published
- 2023
- Full Text
- View/download PDF
15. #3968 DIFFERENCES IN MENTAL HEALTH STATUS DURING COVID-19 PANDEMIC BETWEEN IN-CENTER HEMODIALYSIS AND PERITONEAL DIALYSIS PATIENTS
- Author
-
Bouwmans, Pim, primary, Skalli, Zeinab, additional, Vernooij, Robin, additional, Hemmelder, Marc, additional, Konijn, Wanda, additional, Lips, Joy, additional, Mulder, Janneke, additional, Bonenkamp, Anna, additional, Van Jaarsveld, Brigit, additional, and Abrahams, Alferso C, additional
- Published
- 2023
- Full Text
- View/download PDF
16. Alternative strategies to increase the immunogenicity of COVID-19 vaccines in kidney transplant recipients not responding to two or three doses of an mRNA vaccine (RECOVAC): a randomised clinical trial
- Author
-
Kho, Marcia M L, primary, Messchendorp, A Lianne, additional, Frölke, Sophie C, additional, Imhof, Celine, additional, Koomen, Vera JCH, additional, Malahe, S Reshwan K, additional, Vart, Priya, additional, Geers, Daryl, additional, de Vries, Rory D, additional, GeurtsvanKessel, Corine H, additional, Baan, Carla C, additional, van der Molen, Renate G, additional, Diavatopoulos, Dimitri A, additional, Remmerswaal, Ester B M, additional, van Baarle, Debbie, additional, van Binnendijk, Rob, additional, den Hartog, Gerco, additional, de Vries, Aiko P J, additional, Gansevoort, Ron T, additional, Bemelman, Frederike J, additional, Reinders, Marlies E J, additional, Sanders, Jan-Stephan F, additional, Hilbrands, Luuk B, additional, Abrahams, Alferso C., additional, Baas, Marije C., additional, Bouwmans, Pim, additional, ten Dam, Marc A.G.J., additional, Gommers, Lennert, additional, Standaar, Dorien, additional, van der Heiden, Marieke, additional, Adema, Yvonne M.R., additional, Boer-Verschragen, Marieken J., additional, Mattheussens, Wouter B., additional, Philipsen, Ria H.L.A., additional, van Mourik, Djenolan, additional, Bogers, Susanne, additional, van Dijk, Laura L.A., additional, Rots, Nynke, additional, Smits, Gaby, additional, Kuijer, Marjan, additional, and Hemmelder, Marc H., additional
- Published
- 2023
- Full Text
- View/download PDF
17. Adherence to preventive measures after SARS-CoV-2 vaccination and after awareness of antibody response in kidney transplant recipients in the Netherlands:a nationwide questionnaire study
- Author
-
Frölke, Sophie C., Bouwmans, Pim, Messchendorp, A. Lianne, Vervoort, Johanna P.M., Abrahams, Alferso C., de Vries, Aiko P.J., Nieuwkerk, Pythia T., Hemmelder, Marc H., Gansevoort, Ron T., Hilbrands, Luuk B., Reinders, Marlies E.J., Sanders, Jan Stephan F., Bemelman, Frederike J., Geerlings, Suzanne E., van der Molen, R. G., Frölke, Sophie C., Bouwmans, Pim, Messchendorp, A. Lianne, Vervoort, Johanna P.M., Abrahams, Alferso C., de Vries, Aiko P.J., Nieuwkerk, Pythia T., Hemmelder, Marc H., Gansevoort, Ron T., Hilbrands, Luuk B., Reinders, Marlies E.J., Sanders, Jan Stephan F., Bemelman, Frederike J., Geerlings, Suzanne E., and van der Molen, R. G.
- Abstract
Background: Kidney transplant recipients (KTRs) were advised to tightly adhere to government recommendations to curb the spread of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) because of a high risk of morbidity and mortality and decreased immunogenicity after vaccination. The aim of this study was to analyse the change in adherence to preventive measures after vaccination and awareness of antibody response, and to evaluate its effectiveness. Methods: In this large-scale, national questionnaire study, questionnaires were sent to 3531 KTRs enrolled in the Dutch RECOVAC studies, retrospectively asking for adherence to nine preventive measures on a 5-point Likert scale before and after SARS-CoV-2 vaccination and after awareness of antibody response. Blood samples were collected 28 days after the second vaccination. Antibody response was categorised as non-responder (≤50 BAU/mL), low-responder (>50 ≤ 300 BAU/mL) or high-responder (>300 BAU/mL), and shared with participants as a correlate of protection. Participants of whom demographics on sex and age, blood samples and completed questionnaires were available, were included. Our study took place between February 2021 and January 2022. The primary outcome of adherence before and after vaccination was assessed between August and October 2021 and compared via the Wilcoxon signed rank sum test. Logistic regression analysis was performed to estimate the association between antibody response and non-adherence, and adherence on acquiring SARS-CoV-2 infection. This study is registered at ClinicalTrials.gov (NCT04841785). Findings: In 2939 KTRs (83%) who completed the first questionnaire on adherence to preventive measures, adherence was higher before than after vaccination (4.56, IQR 4.11–4.78 and 4.22, IQR 3.67–4.67, p < 0.001). Adherence after awareness of antibody response was analysed in 2399 KTRs (82%) of whom also blood samples were available, containing 949 non-responders, 500 low-responders an
- Published
- 2023
18. Impact of immunosuppressive treatment and type of SARS-CoV-2 vaccine on antibody levels after three vaccinations in patients with chronic kidney disease or kidney replacement therapy
- Author
-
Bouwmans, Pim, Messchendorp, A Lianne, Imhof, Céline, Sanders, Jan-Stephan F, Hilbrands, Luuk B, Reinders, Marlies E J, Vart, Priya, Bemelman, Frederike J, Abrahams, Alferso C, van den Dorpel, René M A, Ten Dam, Marc A G J, de Vries, Aiko P J, Rispens, Theo, Steenhuis, Maurice, Gansevoort, Ron T, Hemmelder, Marc H, Bouwmans, Pim, Messchendorp, A Lianne, Imhof, Céline, Sanders, Jan-Stephan F, Hilbrands, Luuk B, Reinders, Marlies E J, Vart, Priya, Bemelman, Frederike J, Abrahams, Alferso C, van den Dorpel, René M A, Ten Dam, Marc A G J, de Vries, Aiko P J, Rispens, Theo, Steenhuis, Maurice, Gansevoort, Ron T, and Hemmelder, Marc H
- Abstract
Background. Patients with chronic kidney disease (CKD) or kidney replacement therapy demonstrate lower antibody levels after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination compared with healthy controls. In a prospective cohort, we analysed the impact of immunosuppressive treatment and type of vaccine on antibody levels after three SARS-CoV-2 vaccinations. Methods. Control subjects (n = 186), patients with CKD G4/5 (n = 400), dialysis patients (n = 480) and kidney transplant recipients (KTR) (n = 2468) were vaccinated with either mRNA-1273 (Moderna), BNT162b2 (Pfizer-BioNTech) or AZD1222 (Oxford/AstraZeneca) in the Dutch SARS-CoV-2 vaccination programme. Third vaccination data were available in a subgroup of patients (n = 1829). Blood samples and questionnaires were obtained 1 month after the second and third vaccination. Primary endpoint was the antibody level in relation to immunosuppressive treatment and type of vaccine. Secondary endpoint was occurrence of adverse events after vaccination. Results. Antibody levels after two and three vaccinations were lower in patients with CKD G4/5 and dialysis patients with immunosuppressive treatment compared with patients without immunosuppressive treatment. After two vaccinations, we observed lower antibody levels in KTR using mycophenolate mofetil (MMF) compared with KTR not using MMF [20 binding antibody unit (BAU)/mL (3-113) vs 340 BAU/mL (50-1492), P < .001]. Seroconversion was observed in 35% of KTR using MMF, compared with 75% of KTR not using MMF. Of the KTR who used MMF and did not seroconvert, eventually 46% seroconverted after a third vaccination. mRNA-1273 induces higher antibody levels as well as a higher frequency of adverse events compared with BNT162b2 in all patient groups. Conclusions. Immunosuppressive treatment adversely affects the antibody levels after SARS-CoV-2 vaccination in patients with CKD G4/5, dialysis patients and KTR. mRNA-1273 vaccine induces a higher antibody
- Published
- 2023
19. Kidney Transplant Recipients Become Less Adherent to Preventive Measures after SARS‑CoV‑2 Vaccination and after Awareness of Antibody Response
- Author
-
Frölke, Sophie, primary, Bouwmans, Pim, additional, Messchendorp, A. Lianne, additional, Vervoort, Johanna PM, additional, Nieuwkerk, Pythia T., additional, Hemmelder, Marc H., additional, Gansevoort, Ron T., additional, Hilbrands, Luuk B., additional, Reinders, Marlies EJ, additional, Sanders, Jan-Stephan, additional, Bemelman, Frederike J., additional, Geerlings, Suzanne E., additional, and Collaborators, RECOVAC, additional
- Published
- 2023
- Full Text
- View/download PDF
20. Mycophenolic Acid Exposure Determines Antibody Formation Following SARS‐CoV‐2 Vaccination in Kidney Transplant Recipients: A Nested Cohort Study.
- Author
-
Meziyerh, Soufian, Bouwmans, Pim, van Gelder, Teun, van der Helm, Danny, Messchendorp, Lianne, van der Boog, Paul J. M., de Fijter, Johan W., Moes, Dirk Jan A. R., and de Vries, Aiko P. J.
- Subjects
MYCOPHENOLIC acid ,ANTIBODY formation ,KIDNEY transplantation ,COVID-19 ,COVID-19 vaccines ,IMMUNOGLOBULINS - Abstract
Despite (repeated) boosting, kidney transplant recipients (KTRs) may remain at increased risk of severe COVID‐19 since a substantial number of individuals remain seronegative or with low antibody titers. In particular, mycophenolic acid use has been shown to affect antibody formation negatively and may be an important modifiable risk factor. We investigated the exposure–response relationship between mycophenolic acid 12‐hour area under the curve (AUC0–12h) exposure and seroconversion including antibody titers after vaccination using mRNA‐1273 SARS‐CoV‐2 vaccine (Moderna) in 316 KTRs from our center that participated in the national Dutch renal patients COVID‐19 vaccination – long term efficacy and safety of SARS‐CoV‐2 vaccination in kidney disease patients vaccination study. After two vaccination doses, 162 (51%) KTRs seroconverted. KTRs treated with mycophenolic acid showed less seroconversion and lower antibody titers compared with KTRs without mycophenolic acid (44% vs. 77%, and 36 binding antibody units (BAU)/mL vs. 340 BAU/mL; P < 0.001). The mean mycophenolic acid AUC0–12h exposure was significantly lower in KTRs who seroconverted compared with KTRs who did not (39 vs. 29 mg⋅h/L; P < 0.001). High mycophenolic acid exposure (±90 mg⋅h/L) and no exposure to mycophenolic acid resulted in a seroconversion rate ranging from 10% to 80%. Every 10 mg⋅h/L increase in mycophenolic acid AUC0–12h gave an adjusted odds ratio for seroconversion of 0.87 (95% confidence interval (CI), 0.79–0.97; P = 0.010) and 0.89 (95% CI, 0.85–0.93; P < 0.001) for KTRs on dual and triple maintenance immunosuppressive therapy, respectively. Higher mycophenolic acid AUC0–12h correlated with lower antibody titers (R = 0.44, P < 0.001). This study demonstrates the exposure–response relationship between gold standard mycophenolic acid exposure and antibody formation to support interventional studies investigating mycophenolic acid adjustment to improve antibody formation after further boosting. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
21. The clinical frailty scale is useful for icu triage in dialysis patients with covid-19-an eracoda analysis
- Author
-
Bouwmans, Pim, Brandts, Lloyd, Hilbrands, Luuk, Duivenvoorden, Raphael, Vart, Priya, Franssen, Casper, Jager, Kitty J., Noordzij, Marlies, Gansevoort, Ronald, Hemmelder, Marc, Groningen Kidney Center (GKC), and Cardiovascular Centre (CVC)
- Published
- 2022
22. The Clinical Frailty Scale as a triage tool for ICU admission of dialysis patients with COVID-19: an ERACODA analysis.
- Author
-
UCL - SSS/IREC/NEFR - Pôle de Néphrologie, UCL - (MGD) Service de néphrologie, Bouwmans, Pim, Brandts, Lloyd, Hilbrands, Luuk B, Duivenvoorden, Raphaël, Vart, Priya, Franssen, Casper F M, Covic, Adrian, Islam, Mahmud, Rabaté, Clémentine, Jager, Kitty J, Noordzij, Marlies, Gansevoort, Ron T, Hemmelder, Marc H, ERACODA collaborators, Goffin, Eric, Kanaan, Nada, Labriola, Laura, Devresse, Arnaud, UCL - SSS/IREC/NEFR - Pôle de Néphrologie, UCL - (MGD) Service de néphrologie, Bouwmans, Pim, Brandts, Lloyd, Hilbrands, Luuk B, Duivenvoorden, Raphaël, Vart, Priya, Franssen, Casper F M, Covic, Adrian, Islam, Mahmud, Rabaté, Clémentine, Jager, Kitty J, Noordzij, Marlies, Gansevoort, Ron T, Hemmelder, Marc H, ERACODA collaborators, Goffin, Eric, Kanaan, Nada, Labriola, Laura, and Devresse, Arnaud
- Abstract
Several guidelines recommend using the Clinical Frailty Scale (CFS) for triage of critically ill coronavirus disease 2019 (COVID-19) patients. This study evaluates the impact of CFS on intensive care unit (ICU) admission rate and hospital and ICU mortality rates in hospitalized dialysis patients with COVID-19. We analysed data of dialysis patients diagnosed with COVID-19 from the European Renal Association COVID-19 Database. The primary outcome was ICU admission rate and secondary outcomes were hospital and ICU mortality until 3 months after COVID-19 diagnosis. Cox regression analyses were performed to assess associations between CFS and outcomes. A total of 1501 dialysis patients were hospitalized due to COVID-19, of whom 219 (15%) were admitted to an ICU. The ICU admission rate was lowest (5%) in patients >75 years of age with a CFS of 7-9 and highest (27%) in patients 65-75 years of age with a CFS of 5. A CFS of 7-9 was associated with a lower ICU admission rate than a CFS of 1-3 [relative risk 0.49 (95% confidence interval 0.27-0.87)]. Overall, mortality at 3 months was 34% in hospitalized patients, 65% in ICU-admitted patients and highest in patients >75 years of age with a CFS of 7-9 (69%). Only 9% of patients with a CFS ≥6 survived after ICU admission. After adjustment for age and sex, each CFS category ≥4 was associated with higher hospital and ICU mortality compared with a CFS of 1-3. Frail dialysis patients with COVID-19 were less frequently admitted to the ICU. Large differences in mortality rates between fit and frail patients suggest that the CFS may be a useful complementary triage tool for ICU admission in dialysis patients with COVID-19.
- Published
- 2022
23. The Clinical Frailty Scale as a triage tool for ICU admission of dialysis patients with COVID-19:an ERACODA analysis
- Author
-
Bouwmans, Pim, Brandts, Lloyd, Hilbrands, Luuk B, Duivenvoorden, Raphaël, Vart, Priya, Franssen, Casper F M, Covic, Adrian, Islam, Mahmud, Rabaté, Clémentine, Jager, Kitty J, Noordzij, Marlies, Gansevoort, Ron T, Hemmelder, Marc H, Bouwmans, Pim, Brandts, Lloyd, Hilbrands, Luuk B, Duivenvoorden, Raphaël, Vart, Priya, Franssen, Casper F M, Covic, Adrian, Islam, Mahmud, Rabaté, Clémentine, Jager, Kitty J, Noordzij, Marlies, Gansevoort, Ron T, and Hemmelder, Marc H
- Abstract
Background Several guidelines recommend using the Clinical Frailty Scale (CFS) for triage of critically ill coronavirus disease 2019 (COVID-19) patients. This study evaluates the impact of CFS on intensive care unit (ICU) admission rate and hospital and ICU mortality rates in hospitalized dialysis patients with COVID-19. Methods We analysed data of dialysis patients diagnosed with COVID-19 from the European Renal Association COVID-19 Database. The primary outcome was ICU admission rate and secondary outcomes were hospital and ICU mortality until 3 months after COVID-19 diagnosis. Cox regression analyses were performed to assess associations between CFS and outcomes. Results A total of 1501 dialysis patients were hospitalized due to COVID-19, of whom 219 (15%) were admitted to an ICU. The ICU admission rate was lowest (5%) in patients >75 years of age with a CFS of 7-9 and highest (27%) in patients 65-75 years of age with a CFS of 5. A CFS of 7-9 was associated with a lower ICU admission rate than a CFS of 1-3 [relative risk 0.49 (95% confidence interval 0.27-0.87)]. Overall, mortality at 3 months was 34% in hospitalized patients, 65% in ICU-admitted patients and highest in patients >75 years of age with a CFS of 7-9 (69%). Only 9% of patients with a CFS >= 6 survived after ICU admission. After adjustment for age and sex, each CFS category >= 4 was associated with higher hospital and ICU mortality compared with a CFS of 1-3. Conclusions Frail dialysis patients with COVID-19 were less frequently admitted to the ICU. Large differences in mortality rates between fit and frail patients suggest that the CFS may be a useful complementary triage tool for ICU admission in dialysis patients with COVID-19.
- Published
- 2022
24. MO899: The Clinical frailty Scale is Useful for ICU Triage in Dialysis Patients With COVID-19–An Eracoda Analysis
- Author
-
Bouwmans, Pim, primary, Brandts, Lloyd, additional, Hilbrands, Luuk, additional, Duivenvoorden, Raphael, additional, Vart, Priya, additional, Franssen, Casper, additional, Jager, Kitty J, additional, Noordzij, Marlies, additional, Gansevoort, Ronald, additional, and Hemmelder, Marc, additional
- Published
- 2022
- Full Text
- View/download PDF
25. MO337: Higher Antibody Response After 2 Vaccinations With MRNA-1273 as Compared With BNT162B2 and AZD1222 in High-Risk Kidney Patients
- Author
-
Bouwmans, Pim, primary, Messchendorp, Lianne, additional, Imhof, Celine, additional, Sanders, Jan-Stephan, additional, Hilbrands, Luuk, additional, Vart, Priya, additional, Reinders, Marlies, additional, Bemelman, Frederike, additional, Abrahams, Alferso C, additional, Dorpel van den, René, additional, Ten Dam, Marc, additional, De Vries, Aiko, additional, Rispens, Theo, additional, Steenhuis, Maurice, additional, Gansevoort, Ronald, additional, and Hemmelder, Marc, additional
- Published
- 2022
- Full Text
- View/download PDF
26. MO184: Development and Validation of a Multivariable Prediction Model for Nonseroconversion after SARS-COV-2 Vaccination in Kidney Transplant Recipients
- Author
-
Frölke, Sophie, primary, Bouwmans, Pim, additional, Messchendorp, Lianne, additional, Geerlings, Suzanne, additional, Hemmelder, Marc, additional, Gansevoort, Ronald, additional, Hilbrands, Luuk, additional, Reinders, Marlies, additional, Sanders, Jan-Stephan, additional, Bemelman, Frederike, additional, and Peters-Sengers, H, additional
- Published
- 2022
- Full Text
- View/download PDF
27. The clinical frailty scale as a triage tool for ICU admission of dialysis patients with COVID-19 - An ERACODA analysis
- Author
-
Bouwmans, Pim, Brandts, Lloyd, Hilbrands, Luuk B, Duivenvoorden, Raphaël, Vart, Priya, Franssen, Casper F M, Covic, Adrian, Islam, Mahmud, Rabaté, Clémentine, Jager, Kitty J, Noordzij, Marlies, Gansevoort, Ron T, Hemmelder, Marc H, ERACODA collaborators, Goffin, Eric, Kanaan, Nada, Labriola, Laura, Devresse, Arnaud, UCL - SSS/IREC/NEFR - Pôle de Néphrologie, UCL - (SLuc) Service de néphrologie, Graduate School, Medical Informatics, APH - Quality of Care, APH - Aging & Later Life, ACS - Pulmonary hypertension & thrombosis, APH - Global Health, ACS - Microcirculation, APH - Health Behaviors & Chronic Diseases, Nephrology, AII - Infectious diseases, UCL - (MGD) Service de néphrologie, Interne Geneeskunde, RS: Carim - V02 Hypertension and target organ damage, MUMC+: KIO Kemta (9), RS: GROW - R1 - Prevention, MUMC+: MA Nefrologie (9), Clinical sciences, Internal Medicine, Groningen Kidney Center (GKC), and Cardiovascular Centre (CVC)
- Subjects
Chronic/complications ,COVID-19/diagnosis ,intensive care units ,MULTICENTER ,Fatigue Syndrome, Chronic/complications ,frailty ,infectious diseases ,COVID-19 Testing ,Renal Dialysis ,Humans ,KIDNEY-TRANSPLANT ,Mortality ,Aged ,Transplantation ,Fatigue Syndrome, Chronic ,Frailty ,COVID-19 ,CARE ,Fatigue Syndrome ,mortality ,Intensive Care Units ,Renal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11] ,Frailty/diagnosis ,Nephrology ,dialysis ,Renal disorders Radboud Institute for Health Sciences [Radboudumc 11] ,Triage ,triage ,Dialysis - Abstract
BackgroundSeveral guidelines recommend using the Clinical Frailty Scale (CFS) for triage of critically ill coronavirus disease 2019 (COVID-19) patients. This study evaluates the impact of CFS on intensive care unit (ICU) admission rate and hospital and ICU mortality rates in hospitalized dialysis patients with COVID-19.MethodsWe analysed data of dialysis patients diagnosed with COVID-19 from the European Renal Association COVID-19 Database. The primary outcome was ICU admission rate and secondary outcomes were hospital and ICU mortality until 3 months after COVID-19 diagnosis. Cox regression analyses were performed to assess associations between CFS and outcomes.ResultsA total of 1501 dialysis patients were hospitalized due to COVID-19, of whom 219 (15%) were admitted to an ICU. The ICU admission rate was lowest (5%) in patients >75 years of age with a CFS of 7–9 and highest (27%) in patients 65–75 years of age with a CFS of 5. A CFS of 7–9 was associated with a lower ICU admission rate than a CFS of 1–3 [relative risk 0.49 (95% confidence interval 0.27–0.87)]. Overall, mortality at 3 months was 34% in hospitalized patients, 65% in ICU-admitted patients and highest in patients >75 years of age with a CFS of 7–9 (69%). Only 9% of patients with a CFS ≥6 survived after ICU admission. After adjustment for age and sex, each CFS category ≥4 was associated with higher hospital and ICU mortality compared with a CFS of 1–3.ConclusionsFrail dialysis patients with COVID-19 were less frequently admitted to the ICU. Large differences in mortality rates between fit and frail patients suggest that the CFS may be a useful complementary triage tool for ICU admission in dialysis patients with COVID-19.
- Published
- 2022
28. Clinical Frailty Scale as a triage tool for ICU admission of dialysis patients with COVID-19: an ERACODA analysis.
- Author
-
Bouwmans, Pim, Brandts, Lloyd, Hilbrands, Luuk B, Duivenvoorden, Raphaël, Vart, Priya, Franssen, Casper F M, Covic, Adrian, Islam, Mahmud, Rabaté, Clémentine, Jager, Kitty J, Noordzij, Marlies, Gansevoort, Ron T, Hemmelder, Marc H, and collaborators, for the ERACODA
- Subjects
- *
COVID-19 , *HEMODIALYSIS patients , *HOSPITAL admission & discharge , *FRAILTY , *INTENSIVE care units - Abstract
Background Several guidelines recommend using the Clinical Frailty Scale (CFS) for triage of critically ill coronavirus disease 2019 (COVID-19) patients. This study evaluates the impact of CFS on intensive care unit (ICU) admission rate and hospital and ICU mortality rates in hospitalized dialysis patients with COVID-19. Methods We analysed data of dialysis patients diagnosed with COVID-19 from the European Renal Association COVID-19 Database. The primary outcome was ICU admission rate and secondary outcomes were hospital and ICU mortality until 3 months after COVID-19 diagnosis. Cox regression analyses were performed to assess associations between CFS and outcomes. Results A total of 1501 dialysis patients were hospitalized due to COVID-19, of whom 219 (15%) were admitted to an ICU. The ICU admission rate was lowest (5%) in patients >75 years of age with a CFS of 7–9 and highest (27%) in patients 65–75 years of age with a CFS of 5. A CFS of 7–9 was associated with a lower ICU admission rate than a CFS of 1–3 [relative risk 0.49 (95% confidence interval 0.27–0.87)]. Overall, mortality at 3 months was 34% in hospitalized patients, 65% in ICU-admitted patients and highest in patients >75 years of age with a CFS of 7–9 (69%). Only 9% of patients with a CFS ≥6 survived after ICU admission. After adjustment for age and sex, each CFS category ≥4 was associated with higher hospital and ICU mortality compared with a CFS of 1–3. Conclusions Frail dialysis patients with COVID-19 were less frequently admitted to the ICU. Large differences in mortality rates between fit and frail patients suggest that the CFS may be a useful complementary triage tool for ICU admission in dialysis patients with COVID-19. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
29. Incidence and Severity of COVID-19 in Relation to Anti-Receptor-Binding Domain IgG Antibody Level after COVID-19 Vaccination in Kidney Transplant Recipients.
- Author
-
Messchendorp AL, Sanders JF, Abrahams AC, Bemelman FJ, Bouwmans P, van den Dorpel RMA, Hilbrands LB, Imhof C, Reinders MEJ, Rispens T, Steenhuis M, Ten Dam MAGJ, Vart P, de Vries APJ, Hemmelder MH, Gansevoort RT, and Recovac Investigators
- Subjects
- Humans, Incidence, COVID-19 Vaccines, SARS-CoV-2, Immunoglobulin G, COVID-19 epidemiology, COVID-19 prevention & control, Kidney Transplantation, Spike Glycoprotein, Coronavirus
- Abstract
Kidney transplant recipients (KTRs) elicit an impaired immune response after COVID-19 vaccination; however, the exact clinical impact remains unclear. We therefore analyse the relationship between antibody levels after vaccination and the risk of COVID-19 in a large cohort of KTRs. All KTRs living in the Netherlands were invited to send a blood sample 28 days after their second COVID-19 vaccination for measurement of their IgG antibodies against the receptor-binding domain of the SARS-CoV-2 spike protein (anti-RBD IgG). Information on COVID-19 was collected from the moment the blood sample was obtained until 6 months thereafter. Multivariable Cox and logistic regression analyses were performed to analyse which factors affected the occurrence and severity (i.e., hospitalization and/or death) of COVID-19. In total, 12,159 KTRs were approached, of whom 2885 were included in the analyses. Among those, 1578 (54.7%) became seropositive (i.e., anti-RBD IgG level >50 BAU/mL). Seropositivity was associated with a lower risk for COVID-19, also after adjusting for multiple confounders, including socio-economic status and adherence to COVID-19 restrictions (HR 0.37 (0.19-0.47), p = 0.005). When studied on a continuous scale, we observed a log-linear relationship between antibody level and the risk for COVID-19 (HR 0.52 (0.31-0.89), p = 0.02). Similar results were found for COVID-19 severity. In conclusion, antibody level after COVID-19 vaccination is associated in a log-linear manner with the occurrence and severity of COVID-19 in KTRs. This implies that if future vaccinations are indicated, the aim should be to reach for as high an antibody level as possible and not only seropositivity to protect this vulnerable patient group from disease., Competing Interests: The authors declare no conflicts of interest.
- Published
- 2024
- Full Text
- View/download PDF
30. Impact of immunosuppressive treatment and type of SARS-CoV-2 vaccine on antibody levels after three vaccinations in patients with chronic kidney disease or kidney replacement therapy.
- Author
-
Bouwmans P, Messchendorp AL, Imhof C, Sanders JF, Hilbrands LB, Reinders MEJ, Vart P, Bemelman FJ, Abrahams AC, van den Dorpel RMA, Ten Dam MAGJ, de Vries APJ, Rispens T, Steenhuis M, Gansevoort RT, and Hemmelder MH
- Abstract
Background: Patients with chronic kidney disease (CKD) or kidney replacement therapy demonstrate lower antibody levels after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination compared with healthy controls. In a prospective cohort, we analysed the impact of immunosuppressive treatment and type of vaccine on antibody levels after three SARS-CoV-2 vaccinations., Methods: Control subjects ( n = 186), patients with CKD G4/5 ( n = 400), dialysis patients ( n = 480) and kidney transplant recipients (KTR) ( n = 2468) were vaccinated with either mRNA-1273 (Moderna), BNT162b2 (Pfizer-BioNTech) or AZD1222 (Oxford/AstraZeneca) in the Dutch SARS-CoV-2 vaccination programme. Third vaccination data were available in a subgroup of patients ( n = 1829). Blood samples and questionnaires were obtained 1 month after the second and third vaccination. Primary endpoint was the antibody level in relation to immunosuppressive treatment and type of vaccine. Secondary endpoint was occurrence of adverse events after vaccination., Results: Antibody levels after two and three vaccinations were lower in patients with CKD G4/5 and dialysis patients with immunosuppressive treatment compared with patients without immunosuppressive treatment. After two vaccinations, we observed lower antibody levels in KTR using mycophenolate mofetil (MMF) compared with KTR not using MMF [20 binding antibody unit (BAU)/mL (3-113) vs 340 BAU/mL (50-1492), P < .001]. Seroconversion was observed in 35% of KTR using MMF, compared with 75% of KTR not using MMF. Of the KTR who used MMF and did not seroconvert, eventually 46% seroconverted after a third vaccination. mRNA-1273 induces higher antibody levels as well as a higher frequency of adverse events compared with BNT162b2 in all patient groups., Conclusions: Immunosuppressive treatment adversely affects the antibody levels after SARS-CoV-2 vaccination in patients with CKD G4/5, dialysis patients and KTR. mRNA-1273 vaccine induces a higher antibody level and higher frequency of adverse events., (© The Author(s) 2022. Published by Oxford University Press on behalf of the ERA.)
- Published
- 2022
- Full Text
- View/download PDF
31. The Clinical Frailty Scale as a triage tool for ICU admission of dialysis patients with COVID-19: an ERACODA analysis.
- Author
-
Bouwmans P, Brandts L, Hilbrands LB, Duivenvoorden R, Vart P, Franssen CFM, Covic A, Islam M, Rabaté C, Jager KJ, Noordzij M, Gansevoort RT, and Hemmelder MH
- Subjects
- Humans, Aged, Triage, COVID-19 Testing, Renal Dialysis, Intensive Care Units, Frailty diagnosis, Frailty epidemiology, COVID-19 diagnosis
- Abstract
Background: Several guidelines recommend using the Clinical Frailty Scale (CFS) for triage of critically ill coronavirus disease 2019 (COVID-19) patients. This study evaluates the impact of CFS on intensive care unit (ICU) admission rate and hospital and ICU mortality rates in hospitalized dialysis patients with COVID-19., Methods: We analysed data of dialysis patients diagnosed with COVID-19 from the European Renal Association COVID-19 Database. The primary outcome was ICU admission rate and secondary outcomes were hospital and ICU mortality until 3 months after COVID-19 diagnosis. Cox regression analyses were performed to assess associations between CFS and outcomes., Results: A total of 1501 dialysis patients were hospitalized due to COVID-19, of whom 219 (15%) were admitted to an ICU. The ICU admission rate was lowest (5%) in patients >75 years of age with a CFS of 7-9 and highest (27%) in patients 65-75 years of age with a CFS of 5. A CFS of 7-9 was associated with a lower ICU admission rate than a CFS of 1-3 [relative risk 0.49 (95% confidence interval 0.27-0.87)]. Overall, mortality at 3 months was 34% in hospitalized patients, 65% in ICU-admitted patients and highest in patients >75 years of age with a CFS of 7-9 (69%). Only 9% of patients with a CFS ≥6 survived after ICU admission. After adjustment for age and sex, each CFS category ≥4 was associated with higher hospital and ICU mortality compared with a CFS of 1-3., Conclusions: Frail dialysis patients with COVID-19 were less frequently admitted to the ICU. Large differences in mortality rates between fit and frail patients suggest that the CFS may be a useful complementary triage tool for ICU admission in dialysis patients with COVID-19., (© The Author(s) 2022. Published by Oxford University Press on behalf of the ERA.)
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.